Niagen Bioscience CFO presents at Nasdaq X LD Micro SF summit
- Niagen Bioscience CFO Ozan Pamir presents at Nasdaq X LD Micro SF Summit on September 9, 2026
- Event features 15-minute presentations and breakout sessions for 25 curated public companies
- Pamir available for one-on-one meetings with institutional investors in San Francisco
- Company highlights Tru Niagen as top US NAD+ supplement by revenue in 2025

*this image is generated using AI for illustrative purposes only.
Niagen Bioscience, Inc. (NASDAQ: NAGE) announced that its senior management will participate in the Nasdaq X LD Micro Inaugural SF Summit on September 9, 2026, in San Francisco. The event aims to connect curated public companies with institutional investors.
Conference Details
Nasdaq is partnering with LD Micro to host 25 public companies at the Nasdaq San Francisco office. Each company will deliver a 15-minute presentation followed by a dedicated 15-minute breakout session for investor engagement.
Niagen Bioscience CFO Ozan Pamir is scheduled to present at 11:20 am PT. He will also be available for one-on-one meetings with institutional investors during the conference.
Investor Engagement
Investors interested in scheduling a one-on-one meeting with the Niagen Bioscience management team can contact their respective conference representative or email Niagen@KCSA.com .
About Niagen Bioscience
Niagen Bioscience positions itself as the global authority on NAD+ (nicotinamide adenine dinucleotide) science and healthy aging. Its product portfolio includes Tru Niagen, described as the number one NAD+ boosting oral supplement in the United States based on revenue per the largest U.S. e-commerce marketplace from January 2025 to December 2025. The company also offers Niagen Plus, featuring pharmaceutical-grade intravenous and injectable products available exclusively at clinics with a prescription.
How might the outcome of the Nasdaq X LD Micro Summit influence Niagen Bioscience's institutional investor base and stock liquidity in Q4 2026?
What specific growth metrics or clinical data regarding Tru Niagen and Niagen Plus is CFO Ozan Pamir likely to highlight to justify valuation multiples?
Could the exclusive prescription model for Niagen Plus face regulatory or reimbursement hurdles that might impact its projected revenue contribution?































